Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
July 7, 2026
Nprepared by Vivaniovo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants ALAMEDA, Calif.,